Heilbron B G, Gin K G
Cardiac Ultrasound, Vancouver, Canada.
Int J Clin Pharmacol Ther. 1996 Jun;34(6):231-5.
Congestive heart failure is associated with high morbidity and mortality. Modification of neurohormonal activation by use of angiotensin converting enzyme inhibitors has been shown to decrease symptoms and prolong survival. More recent evidence has suggested that beta-adrenoceptor blocking agent therapy may be also beneficial in patients with congestive heart failure, possibly by down-regulating the activation of the adrenergic system. A large number of randomized trials of beta-adrenoceptor blocking agents in heart failure have been performed. These studies demonstrated improvement in symptoms of congestive heart failure, functional classification, and reduction in the number of patients requiring cardiac transplantation. beta-adrenoceptor blocking agents have not been shown to decrease mortality, however, the current trials have been too small to be conclusive in this regard.
充血性心力衰竭与高发病率和高死亡率相关。使用血管紧张素转换酶抑制剂来改变神经激素激活状态已被证明可减轻症状并延长生存期。最近的证据表明，β-肾上腺素能受体阻滞剂治疗可能对充血性心力衰竭患者也有益，可能是通过下调肾上腺素能系统的激活来实现。已经进行了大量关于β-肾上腺素能受体阻滞剂治疗心力衰竭的随机试验。这些研究表明，充血性心力衰竭的症状、功能分级得到改善，需要心脏移植的患者数量减少。然而，β-肾上腺素能受体阻滞剂尚未被证明能降低死亡率，目前的试验规模太小，在这方面尚无定论。
